TRANSTHERA-B (02617) Sets 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend
Bulletin Express
Mar 19
On 19 March 2026, TransThera Sciences (Nanjing), Inc. (stock code: 02617, “TRANSTHERA-B”) announced that its board of directors will convene on 31 March 2026. The agenda includes:
• Reviewing and approving the consolidated annual results for the financial year ended 31 December 2025 and authorising their publication.
• Considering the declaration of a final dividend, if any.
• Addressing other routine corporate matters.
The board currently comprises Executive Directors Dr. Frank Wu (also Chairman and Chief Executive Officer) and Mr. Wu Di; Non-executive Directors Ms. Jia Zhongxin and Dr. Yi Hua; and Independent Non-executive Directors Mr. Li Shu Pai, Ms. Chui Hoi Yam and Ms. Zheng Zhelan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.